Faron Pharmaceuticals Oy (AIM:FARN)

Market Cap	49.79M -74.1%
Revenue (ttm)	n/a
Net Income	-23.78M
EPS	-0.21
Shares Out	115.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,493
Average Volume	125,553
Open	43.00
Previous Close	43.00
Day's Range	42.33 - 44.00
52-Week Range	41.00 - 270.00
Beta	1.09
RSI	24.72
Earnings Date	Mar 4, 2026

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 33
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: FARN

Financial Performance

Financial numbers in EUR